1. Home
  2. CTVA vs ARGX Comparison

CTVA vs ARGX Comparison

Compare CTVA & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTVA
  • ARGX
  • Stock Information
  • Founded
  • CTVA 2018
  • ARGX 2008
  • Country
  • CTVA United States
  • ARGX Netherlands
  • Employees
  • CTVA N/A
  • ARGX N/A
  • Industry
  • CTVA Farming/Seeds/Milling
  • ARGX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • CTVA Consumer Staples
  • ARGX Health Care
  • Exchange
  • CTVA Nasdaq
  • ARGX Nasdaq
  • Market Cap
  • CTVA 44.9B
  • ARGX 40.4B
  • IPO Year
  • CTVA N/A
  • ARGX 2017
  • Fundamental
  • Price
  • CTVA $61.48
  • ARGX $614.76
  • Analyst Decision
  • CTVA Strong Buy
  • ARGX Strong Buy
  • Analyst Count
  • CTVA 17
  • ARGX 20
  • Target Price
  • CTVA $68.24
  • ARGX $699.56
  • AVG Volume (30 Days)
  • CTVA 3.8M
  • ARGX 448.6K
  • Earning Date
  • CTVA 05-07-2025
  • ARGX 05-08-2025
  • Dividend Yield
  • CTVA 1.11%
  • ARGX N/A
  • EPS Growth
  • CTVA 26.57
  • ARGX N/A
  • EPS
  • CTVA 1.30
  • ARGX 12.78
  • Revenue
  • CTVA $16,908,000,000.00
  • ARGX $2,248,205,000.00
  • Revenue This Year
  • CTVA $4.38
  • ARGX $60.97
  • Revenue Next Year
  • CTVA $3.42
  • ARGX $31.50
  • P/E Ratio
  • CTVA $47.28
  • ARGX $44.63
  • Revenue Growth
  • CTVA N/A
  • ARGX 77.22
  • 52 Week Low
  • CTVA $50.01
  • ARGX $352.77
  • 52 Week High
  • CTVA $66.24
  • ARGX $678.21
  • Technical
  • Relative Strength Index (RSI)
  • CTVA 54.67
  • ARGX 57.38
  • Support Level
  • CTVA $58.58
  • ARGX $593.31
  • Resistance Level
  • CTVA $62.25
  • ARGX $604.77
  • Average True Range (ATR)
  • CTVA 2.07
  • ARGX 21.09
  • MACD
  • CTVA 0.37
  • ARGX 5.10
  • Stochastic Oscillator
  • CTVA 91.30
  • ARGX 98.32

About CTVA Corteva Inc.

Corteva is an agricultural inputs pure play that was formed in 2019 when it was spun off from DowDuPont. The company is a leader in the development of new seed and crop protection products. Seeds generate the majority of profits with the remainder coming from crop protection products. Corteva operates globally, but around half of revenue comes from North America.

About ARGX argenx SE

Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.

Share on Social Networks: